BTEK:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP)

ETF | Others |

Last Closing

USD 4.83

Change

-0.02 (-0.33)%

Market Cap

USD 0.49B

Volume

5.22K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 617.54B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 320.04B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B

ETFs Containing BTEK:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.43% 19% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.43% 18% F 31% F
Trailing 12 Months  
Capital Gain 1.27% 31% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.27% 28% F 43% F
Trailing 5 Years  
Capital Gain 30.82% 54% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.82% 52% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 50.99% 92% A 93% A
Dividend Return 50.99% 91% A- 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 900.63% 6% D- 4% F
Risk Adjusted Return 5.66% 34% F 46% F
Market Capitalization 0.49B 70% C- 60% D-

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.